Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma
Palabras clave
Abstracto
Descripción
This is a single BNCT-facility, non-randomized, non-comparative, prospective, open-label, phase I/II trial to determine the value of BNCT in the treatment of subjects who have undergone surgery for glioblastoma, but glioblastoma has not been treated with radiation therapy or chemotherapy. The neutron irradiation site is the FiR 1 reactor site, located at Otaniemi, Espoo, Finland, about 6 kilometers from the Helsinki University Central Hospital, Helsinki, where patient evaluation and post-irradiation care will take place.
BPA is infused as a fructose complex (BPA-F) into a peripheral vein over 2 hours prior to neutron irradiation. Blood samples will be taken before starting the BPA infusion, and thereafter at 20 to 40 minute intervals during the infusion, following infusion, and after delivering neutron irradiation to monitor the blood boron concentration. The blood samples will be analyzed for boron to estimate the average blood boron level during neutron irradiation. The first 12 patients are treated using a BPA dose of 290 mg/kg, following which the dose of BPA is increased stepwise to 500 mg/kg, provided that unacceptable toxicity will not occur.
All patients will be evaluated for response using CT or magnetic resonance imaging (MRI).
fechas
| Verificado por última vez: | 07/31/2008 |
| Primero enviado: | 06/21/2005 |
| Inscripción estimada enviada: | 06/21/2005 |
| Publicado por primera vez: | 06/22/2005 |
| Última actualización enviada: | 08/13/2008 |
| Última actualización publicada: | 08/17/2008 |
| Fecha de inicio real del estudio: | 04/30/1999 |
| Fecha estimada de finalización primaria: | 07/31/2008 |
| Fecha estimada de finalización del estudio: | 07/31/2008 |
Condición o enfermedad
Intervención / tratamiento
Radiation: A
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: A Active treatment arm. | Radiation: A Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation. |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Histologically confirmed glioblastoma multiforme - Supratentorial location - At least 30% of the tumor volume has been removed at craniotomy as judged from a pre/perioperative MRI - Ability to understand the concept of investigational therapy - Tolerates dexamethasone treatment - Adequate anti-epileptic medication - BNCT can be delivered within 6 weeks from the date of brain surgery - A written informed consent Exclusion Criteria: - Age less than 18 or greater than 75 - The tumor infiltrates into the optic chiasm or into the deep parts of the brain prohibiting delivery of an adequate radiation dose with BNCT - Prior radiation therapy to the brain - Prior chemotherapy, immunotherapy, or gene therapy - Karnofsky performance score <70 - Severe cardiac, liver, or kidney failure - Severe infection - A cardiac pace-maker, or a metal implant in the head and neck region that will prohibit MRI examination - Pregnancy or lactation - Phenylketonuria |
Salir
Medidas de resultado primarias
1. safety [3 years]
Medidas de resultado secundarias
1. tumor response [one year]
2. effect on brain tissue [3 years]
